Viva in Vitro has been recognized with the Research Award at the second edition of the Isaac Peral Foundation Awards, an event that celebrates business and technological excellence in the Region of Murcia. This award highlights our work in the development of a pioneering device that detects NLRP3 inflammasome activity in patients with sepsis, one of the leading causes of mortality worldwide. This achievement not only underlines our commitment to biotechnological innovation, but also reinforces our goal of improving quality of life through applied science.
The gala, which took place in the emblematic Isaac Peral auditorium in Cartagena, brought together more than 200 representatives from the political, social and business spheres, and was presented by the journalist María Pina. Viva in Vitro shared the stage with other leading companies such as PcComponentes, awarded as Company of the Year; Hefame, recognized for its business trajectory; and Emuasa, awarded for its innovative project LIFE CONQUER.
The Research Award we have received is a recognition for the entire Viva in Vitro team. Our NLRP3 inflammasome detection device is not only a key breakthrough in sepsis diagnostics, but also opens new avenues for research in inflammatory diseases. This award not only recognizes our technological innovation, but also the potential of our solutions to transform medical diagnostics and save lives.
The Isaac Peral Foundation is an institution that promotes the economic, technological and industrial development of the Region of Murcia. The awards presented reflect the effort and commitment of local companies to innovation and sustainability. Like Viva in Vitro, companies such as PcComponentes and Hefame are demonstrating that the region is a benchmark in the national and international arena, actively contributing to the expansion of the business and technological fabric.
Receiving this award is an incentive to continue our commitment to research and development in biotechnology. At Viva in Vitro, we remain focused on taking our technology to new fields of research, always committed to offering scientific solutions that have a positive impact on society.
This award reaffirms our goal: to be leaders in biotechnology through continuous innovation, based on scientific excellence and our commitment to human welfare.
